Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421–34.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lambert JM, Berkenblit A. Antibody-drug conjugates for cancer treatment. Annu Rev Med. 2018;69:191–207.

CAS  PubMed  Article  Google Scholar 

Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25(20):4764.

CAS  PubMed Central  Article  Google Scholar 

Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.

CAS  PubMed  Article  Google Scholar 

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804.

CAS  PubMed  Article  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–44.

PubMed  PubMed Central  Article  Google Scholar 

Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109(1):74–103.

CAS  PubMed  Article  Google Scholar 

Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18(11):2282–92.

CAS  PubMed  Article  Google Scholar 

Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478–84.

CAS  PubMed  Article  Google Scholar 

Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A. 2014;111(5):1766–71.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70.

CAS  PubMed  Article  Google Scholar 

McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. Aaps j. 2015;17(2):339–51.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates. Mol Cancer Ther. 2022;21(2):310–21. Impact translational study investigating the physiochemical properties and mechanisms of action behind the bystander effect for various antibody-drug conjugate payloads.

CAS  PubMed  Article  Google Scholar 

Frigerio M, Kyle AF. The chemical design and synthesis of linkers used in antibody drug conjugates. Curr Top Med Chem. 2017;17(32):3393–424.

CAS  PubMed  Article  Google Scholar 

Wada R, Erickson HK, Lewis Phillips GD, Provenzano CA, Leipold DD, Mai E, et al. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol. 2014;74(5):969–80.

CAS  PubMed  Article  Google Scholar 

Heinmöller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M, et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 2003;9(14):5238–43.

PubMed  Google Scholar 

Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;86(9):1449–56.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003;9(10 Pt 1):3645–52.

CAS  PubMed  Google Scholar 

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–6.

CAS  PubMed  Article  Google Scholar 

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020;10(5):674–87.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Network NCC. Non-small cell lung cancer (Version 5.2021) 2021 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13(2):273–9.

CAS  PubMed  Article  Google Scholar 

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64–72.

CAS  PubMed  Article  Google Scholar 

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108.

CAS  PubMed  Article  Google Scholar 

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241–51. Published results of the phase 2 DESTINY-Lung01 trial showing impressive durable anti-tumor activity for trastuzumab deruxtecan in HER2-mutated NSCLC.

CAS  PubMed  Article  Google Scholar 

Nakagawa K, Nagasaka M, Felip E, Pacheco J, Baik C, Goto Y, et al. OA04.05 trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01. J Thorac Oncol. 2020;16(3, Supplement):S109–10.

Article  Google Scholar 

Suenaga A, Takada N, Hatakeyama M, Ichikawa M, Yu X, Tomii K, et al. Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem. 2005;280(2):1321–6.

CAS  PubMed  Article  Google Scholar 

Li Q, Zhang R, Yan H, Zhao P, Wu L, Wang H, et al. Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget. 2017;8(40):67140–51.

PubMed  PubMed Central  Article  Google Scholar 

Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019;9(1):7406.

PubMed  PubMed Central  Article  Google Scholar 

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.

CAS  PubMed  Article  Google Scholar 

Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12(1):74–89. Published results of the multi-center, global, dose-escalation and -expansion study of HER3-DXd in EGFR TKI-resistant advanced EGFR-mutated NSCLC. HER3-DXd demonstrated durable antitumor activity across a range of EGFR TKI resistance mechanisms.

PubMed  Article  Google Scholar 

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496–512.

PubMed  PubMed Central  Article  Google Scholar 

Mito R, Matsubara E, Komohara Y, Shinchi Y, Sato K, Yoshii D, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70(5):287–94.

CAS  PubMed  Article  Google Scholar